Latest news

• Novartis’ Extavia evades NICE restrictions on MS drugs

  But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down. ... The appraisal rejected four other interferons - Biogen’s Avonex and long-acting variant Plegridy, Bayer’s Betaferon, and Merck Serono’s Rebif - as well as Teva’s

• Xarelto and Eylea continue to dominate Bayer's pharma sales

  treatment Betaferon/Betaseron (down 11% to 734m).

• Bayer CEO Dekkers points to 'outstanding' pharma growth

  a year at peak and compensating for slowing sales of older products such as Betaferon/Betaseron (interferon beta-1b) for multiple sclerosis.

• FDA approves Biogen Idec's long-acting MS therapy

  The new long-acting formulation will give Biogen Idec a competitive advantage over interferon rivals such as Bayer's Betaferon/Betaseron (interferon beta-1b) and Merck Serono/Pfizer's Rebif (interferon

• Plegridy approval underlines Biogen Idec's dominance in MS

  Plegridy's dosing gives Biogen Idec a competitive advantage over Avonex rivals such as Bayer's Betaferon/Betaseron (interferon beta-1b) and Merck Serono/Pfizer's Rebif (interferon beta-1a), and